跳轉到

Q63. A 60-year-old patient with AL amyloidosis is being evaluated for eligibility for autologous hematopoietic stem cell transplantation (ASCT). The patient has impaired cardiac and renal function but still meets initial ASCT screening criteria. Which of the following statements regarding ASCT in AL amyloidosis is least accurate?

  • (A) Compared to patients with other hematologic cancers, AL amyloidosis patients often present with significant visceral organ dysfunction, placing them at a higher risk for complications following high-dose chemotherapy.
  • (B) Despite the ongoing controversy regarding the role of ASCT in AL amyloidosis, current registry data show a significant reduction in day 100 treatment-related mortality from 20% to 5% and improved 5-year survival rates.
  • (C) The best outcomes with ASCT in AL amyloidosis are generally observed in patients with renal involvement, though those with early cardiac or liver involvement also derive benefit.
  • (D) Organ responses after ASCT can be delayed, sometimes taking up to 36 months to be observed. For patients achieving a hematologic complete response post-ASCT, the 10-year overall survival rate is approximately 80%.
  • (E) A small prospective randomized controlled trial comparing low-dose oral MDex with ASCT showed no significant difference in hematologic response rates or overall survival (after correcting for high treatment-related mortality), indicating that ASCT offers limited benefit for all AL amyloidosis patients.
點此顯示正解

(E) A small prospective randomized controlled trial comparing low-dose oral MDex with ASCT showed no significant difference in hematologic response rates or overall survival (after correcting for high treatment-related mortality), indicating that ASCT offers limited benefit for all AL amyloidosis patients.

詳解

Why (E) is the LEAST ACCURATE Statement

Statement (E) is false because it overgeneralizes the negative findings from the French randomized trial (Jaccard et al., NEJM 2007) and incorrectly concludes that ASCT "offers limited benefit for all AL amyloidosis patients."45[^9] The trial showed very high treatment-related mortality (24%, or 9 deaths among 37 patients) in the ASCT arm, which rendered the study inconclusive and reflected poor patient selection and performance at low-volume centers in that era.[8][9] However, this does not mean ASCT lacks benefit for appropriately selected patients.

In the modern era with improved patient selection criteria, ASCT provides substantial benefit to eligible patients. Observational studies from 2010-2016 demonstrate median overall survival of 10 years in highly selected patients who underwent ASCT, with patients achieving hematologic complete response having median overall survival of 15 years and 30% surviving more than 20 years.1[^7] Treatment-related mortality has declined dramatically from approximately 14.5% in 1996-2002 to 2.4% in 2010-2016 at experienced centers.[^11] ASCT achieves hematologic complete response in 40% of patients with median duration of 12.3 years.1[^7]

The key is appropriate patient selection—only 10-25% of AL amyloidosis patients are eligible for ASCT based on age, performance status, cardiac function, renal function, and extent of organ involvement.1[7][9] For this carefully selected subset, ASCT remains a highly effective first-line therapy that provides durable responses and prolonged survival.[8][11]

Why (A), (B), (C), and (D) are ACCURATE

(A) is accurate: AL amyloidosis patients present with significant visceral organ dysfunction from amyloid deposition, which places them at higher risk for complications following high-dose chemotherapy compared to patients with other hematologic malignancies.3[^7] This organ dysfunction—particularly cardiac involvement—contributes to hemodynamic instability and increased morbidity and mortality during ASCT.3

(B) is accurate: Registry data demonstrate a significant reduction in day 100 treatment-related mortality from approximately 20% (14.5% in 1996-2002) to less than 5% (2.4% in 2010-2016), with corresponding improvements in 5-year survival rates.[8][11] This improvement reflects better patient selection criteria, risk-adapted melphalan dosing, and enhanced supportive care at experienced centers.1[7][11]

(C) is accurate: The best outcomes with ASCT are observed in patients with renal involvement without significant cardiac disease.3 Patients with cardiac involvement have worse outcomes—in one series, median survival was 6.4 years without cardiac involvement versus 1.6 years with cardiac involvement.3 However, patients with early cardiac involvement (not advanced heart failure) can still derive benefit with careful selection.[7][9] Liver involvement also confers higher risk.3

(D) is accurate: Organ responses after ASCT can be delayed up to 36 months as amyloid deposits slowly regress following elimination of the amyloidogenic light chains.1 Patients achieving hematologic complete response post-ASCT have 10-year overall survival of approximately 80% (median overall survival 15 years, with 30% surviving >20 years).1[^7] This underscores the importance of achieving deep hematologic responses for long-term outcomes.

詳解 · 中文翻譯

為何 (E) 是最不精確敘述

敘述 (E) 是 虛假的，因為它過度泛化來自法國隨機試驗（Jaccard et al., NEJM 2007）的負面發現，並錯誤地得出 ASCT「對所有 AL 澱粉樣變患者提供有限益處」的結論45[^9]。試驗在 ASCT 臂中顯示非常高的治療相關死亡率（24%，或 37 名患者中 9 人死亡），這使研究無結論，並反映那個時代在低容量中心的差患者選擇和表現[8][9]。然而，這 不表示 ASCT 對適當選擇患者缺乏益處。

在具改善患者選擇標準的現代時代，ASCT 對合格患者提供實質益處。來自 2010-2016 的觀察性研究證示在高度選擇進行 ASCT 的患者中中位整體存活 10 年，達到血液學完全應答的患者有中位整體存活 15 年且 30% 存活超過 20 年1[^7]。治療相關死亡率已從 1996-2002 年的約 14.5% 戲劇性下降至經驗豐富的中心的 2.4%（2010-2016）[^11]。ASCT 在 40% 的患者中達到血液學完全應答，中位持續時間 12.3 年1[^7]。

關鍵是適當患者選擇—僅 10-25% 的 AL 澱粉樣變患者基於年齡、表現狀態、心臟功能、腎臟功能及器官受累範圍對 ASCT 有資格1[7][9]。對此仔細選擇的亞群，ASCT 仍保留為高度有效的一線治療，提供持久應答及延長存活[8][11]。

為何 (A)、(B)、(C) 及 (D) 精確

(A) 精確：AL 澱粉樣變患者由澱粉樣沉積器官提呈顯著內臟器官功能不全，相比其他血液惡性腫瘤患者，置於高度風險於高劑量化療後併發症3[^7]。此器官功能不全—特別是心臟受累—貢獻於血液動力學不穩定性及增加 ASCT 期間的發病率和死亡率3。

(B) 精確：登記資料證示 日 100 治療相關死亡率的顯著減少，從約 20%（1996-2002 年的 14.5%）至少於 5%（2010-2016 年的 2.4%），伴隨 5 年存活率的相應改善[8][11]。此改善反映經驗豐富的中心更好患者選擇標準、風險適應性 melphalan 劑量及增強支援性護理1[7][11]。

(C) 精確：ASCT 的最佳預後在有腎臟受累無顯著心臟病患者中被觀察3。有心臟受累的患者預後較差—在一項系列中，中位存活無心臟受累是 6.4 年 versus 有心臟受累 1.6 年3。然而，具有早期心臟受累（不是晚期心臟衰竭）的患者仍可通過仔細選擇獲益[7][9]。肝臟受累也賦予更高風險3。

(D) 精確：ASCT 後器官應答可延遲至 36 個月，當澱粉樣沉積隨消除致澱粉樣光鏈之後緩慢消退1。達到 ASCT 後血液學完全應答的患者有約 80% 的 10 年整體存活（中位整體存活 15 年，30% 存活 >20 年）1[^7]。此強調達到深血液學應答對長期預後的重要性。

參考文獻 (AMA)

  1. Gertz MA, Dispenzieri A. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. Jama. 2020;324(1):79-89. doi:10.1001/jama.2020.5493. PMID:32633805. ↩↩↩↩↩↩↩↩↩↩↩↩

  2. Gustine JN, Staron A, Szalat RE, et al. Predictors of Hematologic Response and Survival With Stem Cell Transplantation in AL Amyloidosis: A 25-Year Longitudinal Study. American Journal of Hematology. 2022;97(9):1189-1199. doi:10.1002/ajh.26641. PMID:35731907. ↩

  3. Sanchorawala V. Systemic Light Chain Amyloidosis. The New England Journal of Medicine. 2024;390(24):2295-2307. doi:10.1056/NEJMra2304088. PMID:38924733. ↩↩↩↩↩↩↩↩↩↩

  4. Sidiqi MH, Aljama MA, Buadi FK, et al. Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2018;36(13):1323-1329. doi:10.1200/JCO.2017.76.9554. PMID:29558277. ↩↩

  5. Bozkurt B, Colvin M, Cook J, et al. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. Circulation. 2016;134(23):e579-e646. doi:10.1161/CIR.0000000000000455. PMID:27832612. ↩↩

Figures